Piper Sandler Reiterates “Neutral” Rating for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “neutral” rating restated by research analysts at Piper Sandler in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $43.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $45.00. Piper Sandler’s price objective suggests a potential upside of 48.81% from the company’s previous close.

Several other analysts have also weighed in on the company. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Needham & Company LLC dropped their target price on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday. Finally, Zacks Research cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $52.60.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL traded down $0.21 during trading on Friday, hitting $28.90. 442,488 shares of the stock were exchanged, compared to its average volume of 479,968. The company has a market cap of $937.10 million, a PE ratio of 14.17 and a beta of 0.73. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The company has a fifty day moving average price of $34.86 and a two-hundred day moving average price of $37.13. Collegium Pharmaceutical has a 12-month low of $28.01 and a 12-month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $199.88 million during the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.Collegium Pharmaceutical’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the business posted $1.68 EPS. On average, analysts forecast that Collegium Pharmaceutical will post 6.76 EPS for the current year.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Group One Trading LLC purchased a new stake in Collegium Pharmaceutical during the 4th quarter worth about $28,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares during the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth about $61,000. PNC Financial Services Group Inc. raised its position in shares of Collegium Pharmaceutical by 42.2% in the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 418 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares during the period.

Key Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Collegium reported second-quarter adjusted EPS of $1.92, above the roughly $1.68-$1.72 analyst estimates and up from $1.68 a year earlier. Revenue reached $199.9 million, up 6% year over year and broadly in line with estimates. Collegium Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The ADHD portfolio continued to grow: JORNAY PM revenue increased 41% to $46.1 million, while the newly acquired AZSTARYS contributed $12.9 million during its partial quarter. Collegium also raised its 2026 AZSTARYS revenue outlook to $65 million-$75 million from $60 million-$70 million. 2026 Q2 Results Earnings Presentation
• Positive Sentiment: Operating cash flow was a solid $71.3 million, and adjusted EBITDA rose 8% year over year to $113.8 million, supporting the company’s ability to integrate AZSTARYS and invest in growth.
• Neutral Sentiment: Needham lowered its price target to $46 from $56 but maintained a Buy rating, implying substantial long-term upside despite reduced near-term expectations. Needham Price Target Update
• Negative Sentiment: Collegium cut 2026 product revenue guidance to $825 million-$855 million from $865 million-$895 million, below the approximately $872.4 million consensus estimate. Adjusted EBITDA guidance also fell to $445 million-$470 million from $475 million-$500 million, primarily because of lower pricing and sales for authorized generic Nucynta products.
• Negative Sentiment: The pain portfolio declined 9% year over year to $140.9 million; Nucynta franchise revenue fell 24% and Xtampza ER revenue fell 14%. GAAP results also showed a $15.1 million net loss, while operating expenses increased 45%, partly reflecting acquisition-related costs. Collegium Q2 Earnings and Guidance
• Negative Sentiment: An analyst downgrade contributed to the shares reaching a new 12-month low, reinforcing concerns about slowing pain-product sales and the lowered outlook. Collegium Hits New 12-Month Low on Analyst Downgrade

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.